Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study

dc.creatorLuetkemeyer, Anne F.
dc.creatorRosenkranz, Susan L.
dc.creatorLu, Darlene
dc.creatorMarzan, Florence
dc.creatorIve, Prudence
dc.creatorHogg, Evelyn
dc.creatorSwindells, Susan
dc.creatorBenson, Constance A.
dc.creatorGrinsztejn, Beatriz
dc.creatorSanne, Ian M.
dc.creatorHavlir, Diane V.
dc.creatorAweeka, Francesca
dc.creatorAdult AIDS Clinical Trials Group A5221 Study Team
dc.date.accessioned2018-11-05T16:33:39Z
dc.date.accessioned2023-09-05T16:14:57Z
dc.date.available2018-11-05T16:33:39Z
dc.date.available2023-09-05T16:14:57Z
dc.date.created2018-11-05T16:33:39Z
dc.date.issued2013
dc.identifierLUETKEMEYER, Anne F. et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clinical infectious diseases, v. 57, n. 4, p. 586-593, 2013.
dc.identifier1058-4838
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/29851
dc.identifier10.1093/cid/cit246
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8676101
dc.languageeng
dc.rightsrestricted access
dc.titleRelationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study
dc.typeArticle


Este ítem pertenece a la siguiente institución